Work With Us
- Home
- Work with us
What our assay can do for you
We provide combined genotyping and MRD assays for research purposes across all cancers. Our particular expertise is in lymphomas and hematological cancers. Beyond our standard assays we can integrate individual, exploratory features in collaboration projects. Please contact us for more information.
Minimal Residual Disease
Genotyping
Bespoke Features
Medical Services
Typical sampling flow for individual patients
A blood sample is sent to Liqomics and analyzed to identify tumor variants in the circulating tumor DNA to genotype the tumor and identify variants to track over time for MRD detection.
Blood samples are sent to Liqomics and the identified tumor variants identifying each tumor are used to track minimal residual disease (MRD) at extremely high accuracy.
Blood samples are sent to Liqomics for monitoring of patients in remission. An increase in MRD can trigger a new treatment much earlier than a radiological relapse.
Cancers we cover
We have a highly sensitive combined MRD and genotyping assay for all lymphomas readily available. Assays for solid tumors such as lung cancer, gynecological tumors or pancreatic cancer can easily be designed for individual projects, leveraging our unique platform. Specific genomic targets that are of interest for your project can easily be included. Please contact us for more information.
Lymphoma
Lung Cancer
Gynecological Tumors
Pancreatic Cancer
Other Cancers
What cancers do we cover
We have a highly sensitive combined MRD and genotyping assay for all lymphomas readily available. Assays for solid tumors such as lung cancer, gynecological tumors or pancreatic cancer can easily be designed for individual projects, leveraging our unique platform. Specific genomic targets that are of interest for your project can easily be included. Please contact us for more information.
Treatment start / Patient enrollment
A blood sample is sent to Liqomics and analyzed to identify tumor variants in the circulating tumor DNA to genotype the tumor and identify variants to track over time for MRD detection.
During Treatment
Blood samples are sent to Liqomics and the identified tumor variants identifying each tumor are used to track minimal residual disease (MRD) at extremely high accuracy.
After Treatment / Monitoring
Blood samples are sent to Liqomics for monitoring of patients in remission. An increase in MRD can trigger a new treatment much earlier than a radiological relapse.
What we can do for you if you are a CRO or Pharmaceutical Company
How We Work
Publications
Here are some publications from our early development showing applications in Hodgkin Lymphoma and CNS Lymphoma.
Best Healthcare
General Research Services
Whether you are working at an academic institution or in industry, if you plan to sequence cell-free DNA and analyze circulating tumor DNA please get in contact with us. We will work with you to design a project for your needs.
Our standard assays can be used for genotyping, MRD and relapse detection. Bespoke features can be added for individual projects.